Try our Advanced Search for more refined results
FEDERAL TRADE COMMISSION v. ABBVIE INC et al
Case Number:
2:14-cv-05151
Court:
Nature of Suit:
Judge:
Firms
Companies
Government Agencies
Sectors & Industries:
-
February 19, 2016
AbbVie, Besins Look To Block Doc Requests In AndroGel Suit
AbbVie Inc. and Besins Healthcare Inc. on Thursday told a Pennsylvania federal court they have already given the FTC all non-protected documents from various sources in the agency's pay-for-delay suit over the testosterone treatment Androgel, arguing further requests are excessive and burdensome.
-
February 05, 2016
FTC Wants Patent Prosecution Docs In Androgel Fight
The fight over discoverable documents in a pay-for-delay suit over testosterone replacement treatment AndroGel continued Thursday, when the Federal Trade Commission filed three motions seeking to force AbbVie Inc. and other drugmakers to turn over documents it says are related to the drug's patent.
-
December 15, 2015
FTC To Get Its Mitts On AbbVie Docs In Pay-For-Delay Suit
A Pennsylvania federal court Monday ordered Abbvie Inc. to hand over to the Federal Trade Commission a number of documents pertinent to a pay-for-delay suit over testosterone replacement treatment AndroGel, saying the documents were not privileged because they were created for business purposes, not litigation.
-
October 05, 2015
AbbVie Docs Not Privileged In Pay-For-Delay Suit, FTC Says
AbbVie Inc. has improperly clawed back documents in a pay-for-delay suit over testosterone replacement treatment AndroGel and wrongly told the court that certain documents are privileged, the Federal Trade Commission told a Pennsylvania federal judge Friday.
-
September 28, 2015
AbbVie Calls Docs Sought In Pay-For-Delay Suit Privileged
AbbVie Inc. and Besins Healthcare Inc. told a Pennsylvania federal judge Friday that documents requested by the Federal Trade Commission in a pay-for-delay suit over testosterone replacement treatment AndroGel are privileged and should not be disclosed.
-
September 10, 2015
AbbVie, Besins Told To Give Judge Disputed Docs In FTC Fight
A Pennsylvania federal judge on Wednesday told AbbVie Inc. and Besins Healthcare Inc. to turn over materials they claim are privileged so he can decide whether the Federal Trade Commission should get to see them amid a pay-for-delay suit over testosterone replacement treatment AndroGel.
-
September 08, 2015
FTC Says AbbVie Can't Shield Docs In Pay-For-Delay Fight
The Federal Trade Commission asked a Pennsylvania federal judge Friday to force AbbVie Inc. and Besins Healthcare Inc. to turn over materials in the antitrust watchdog's pay-for-delay suit over AndroGel, saying the drugmakers were wrongly trying to shield important materials.
-
August 26, 2015
FTC Can't Go Straight To 3rd Circ. In AbbVie Antitrust Fight
A Pennsylvania federal judge rejected the Federal Trade Commission's request Wednesday to immediately appeal the dismissal of its pay-for-delay antitrust claims against AbbVie Inc. and Teva Pharmaceuticals USA Inc. over testosterone replacement treatment AndroGel.
-
August 25, 2015
FTC Loses Reconsideration Bid In AbbVie Pay-For-Delay Suit
A Pennsylvania federal judge refused Tuesday to revive the Federal Trade Commission's pay-for-delay antitrust claims against AbbVie Inc. and Teva Pharmaceuticals USA Inc. over Androgel, saying the Third Circuit's recent ruling in litigation over Lamictal didn't affect his analysis.
-
August 10, 2015
FTC Defends Bid For Review In AbbVie Pay-For-Delay Suit
The Federal Trade Commission on Friday defended its bid to have a judge reconsider the dismissal of its pay-for-delay claims against AbbVie Inc. and other drugmakers over the testosterone drug AndroGel, saying the defendants have largely ignored the agency's arguments in light of a new precedent issued by the Third Circuit.